NTRK1 and neoplasm: As a novel multi-targeted receptor tyrosine kinase inhibitor that inhibits pro-angiogenic signaling pathways, the anti-tumor effects of anlotinib in solid tumors are largely attributed to the suppression of tumor angiogenesis (32–35).